Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients’ quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.
Zebrafish study uncovers how ketamine affects brain cells to treat depression
The decades-old anesthetic ketamine could be a game changer for treating severe depression, but there are still many questions about how the drug works, including
December 17, 2024